Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 3 |
2019 | 2 |
2020 | 3 |
2021 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
Br J Haematol. 2020 Apr;189(1):e9-e13. doi: 10.1111/bjh.16406. Epub 2020 Feb 4.
Br J Haematol. 2020.
PMID: 32017058
Free PMC article.
No abstract available.
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
Godwin CD, Laszlo GS, Fiorenza S, Garling EE, Phi TD, Bates OM, Correnti CE, Hoffstrom BG, Lunn MC, Humbert O, Kiem HP, Turtle CJ, Walter RB.
Godwin CD, et al. Among authors: bates om.
Leukemia. 2021 Sep;35(9):2496-2507. doi: 10.1038/s41375-021-01160-1. Epub 2021 Feb 15.
Leukemia. 2021.
PMID: 33589747
Free PMC article.
Item in Clipboard
Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.
Godwin CD, Bates OM, Jean SR, Laszlo GS, Garling EE, Beddoe ME, Cardone MH, Walter RB.
Godwin CD, et al. Among authors: bates om.
Leuk Lymphoma. 2020 Dec;61(12):2990-2994. doi: 10.1080/10428194.2020.1786553. Epub 2020 Jul 4.
Leuk Lymphoma. 2020.
PMID: 32627634
Free PMC article.
No abstract available.
Item in Clipboard
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo RR, Kiem HP, Walter RB.
Humbert O, et al. Among authors: bates om.
Leukemia. 2019 Mar;33(3):762-808. doi: 10.1038/s41375-018-0277-8. Epub 2018 Oct 5.
Leukemia. 2019.
PMID: 30291334
No abstract available.
Item in Clipboard
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
Godwin CD, Laszlo GS, Wood BL, Correnti CE, Bates OM, Garling EE, Mao ZJ, Beddoe ME, Lunn MC, Humbert O, Kiem HP, Walter RB.
Godwin CD, et al. Among authors: bates om.
Leukemia. 2020 Sep;34(9):2479-2483. doi: 10.1038/s41375-020-0755-7. Epub 2020 Feb 18.
Leukemia. 2020.
PMID: 32071429
Free PMC article.
No abstract available.
Item in Clipboard
Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.
Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.
Laszlo GS, et al. Among authors: bates om.
Haematologica. 2019 Feb;104(2):e59-e62. doi: 10.3324/haematol.2018.202069. Epub 2018 Aug 16.
Haematologica. 2019.
PMID: 30115657
Free PMC article.
No abstract available.
Item in Clipboard
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB.
Correnti CE, et al. Among authors: bates om.
Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31.
Leukemia. 2018.
PMID: 29588544
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite